75岁及以上胶质母细胞瘤患者接受辅助治疗的生存结局
本研究基于前瞻性数据库,分析75岁及以上胶质母细胞瘤患者接受调强放疗后的生存结局。108例患者中,中位生存期为10个月,12个月和24个月生存率分别为35.6%和7.9%。多因素分析显示仅化疗使用与生存显著相关,提示部分老年患者可从IMRT联合替莫唑胺中获益。
要点
- 75岁及以上GBM患者IMRT后中位生存期10个月,12个月生存率35.6%。
- 单因素分析中年轻、体能状态好、切除范围大及使用TMZ与生存相关。
核心结论
- 尽管老年GBM患者预后较差,部分选择患者接受IMRT可获生存获益,加用TMZ可进一步延长生存。
研究设计与样本
- 前瞻性数据库分析,纳入2007年5月至2015年12月接受IMRT的GBM患者,分析诊断时年龄≥75岁的108例患者数据。
主要发现
- 108例中35例仅支持治疗,1例仅TMZ,40例仅放疗,32例放化疗联合;58例接受40 Gy低分割IMRT,11例接受60 Gy长程放疗。
- 中位年龄79岁,74-80岁占61.6%,>80岁占38.4%;随访期间64例死亡,中位生存期10个月(95%CI 7.1-11.9),12个月生存率35.6%,24个月生存率7.9%。
临床怎么用
- 对选择性的75岁以上GBM患者,可考虑IMRT辅助治疗,并联合TMZ以潜在延长生存。
局限性
- 当前数据对>75岁GBM患者代表性不足,需进一步研究并明确合适的选择标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the outcomes of the most elderly cohort of patients with a diagnosis of glioblastoma multiforme (GBM) after intensity modulated radiation therapy (IMRT). METHODS AND MATERIALS: The data of patients with GBM who had underwent IMRT from May 2007 to December 2015 were entered into a prospective database. Analysis was performed on the data from patients diagnosed during or after 75 years of age. The primary endpoint was the median survival. Univariate and multivariate analyses were performed with respect to survival for patients aged 74 to 80 versus >80 years, Eastern Cooperative Oncology Group performance status of 0 to 1 versus 2 to 3, extent of resection, a high radiation dose (60 Gy) versus any hypofractionated schedule, MGMT methylation status, planning target volume, and the use of temozolomide (TMZ) versus no TMZ. RESULTS: Of the 108 patients, 35 received best supportive care, 1 received TMZ alone, 40 received RT alone, and 32 received combined RT and TMZ. IMRT was delivered with a hypofractionated technique (40 Gy) in 58 patients or long-course RT (60 Gy) in 11 patients. The median age was 79 years, with 61.6% of patients aged 74 to 80 years and 38.4% aged >80 years. Of the 108 patients, 64 died during the follow-up period, with a median survival of 10 months (95% confidence interval 7.1-11.9), projected 12-month survival rate of 35.6%, and 24-month survival rate of 7.9%. On univariate analysis, the independent predictors of survival included younger age (P=.02), better performance status (P=.014), greater resection extent (P=.002), and TMZ use (P<.001). MGMT methylation status, RT dose, and planning target volume showed no significant differences between the groups. Only chemotherapy use remained statistically significant (P=.035) on multivariate analysis. CONCLUSION: The current data underrepresent elderly patients aged >75 years with GBM. Despite elderly patients having a worse prognosis, the results of the present study suggest the presence of survival benefits with IMRT for selected patients that can be further extended with addition of TMZ. Further study of this cohort and an understanding of the appropriate selection criteria are warranted.
引用
- Harris G, Jayamanne D, Wheeler H, et al. Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy. Int J Radiat Oncol Biol Phys. 2017. PMID: 28602411. doi:10.1016/j.ijrobp.2017.02.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。